During tumor development, cancer cells evolve complex strategies to elude immune surveillance, a process aimed at restraining cancer cell proliferation and involving multiple cell types, such as natural killer (NK) cells and T lymphocytes, and numerous immune factors, such as IL-2, tumor necrosis factor (TNF)-α and IFN-γ [7]. This evidence concerns the gene IFNG and cancer.